Evaxion launches enhanced AI-Immunology™ platform for vaccine antigen prediction | 19.09.24

• The new version 5.0 of the AI ​​model EDEN™ features a novel toxin antigen predictor, is trained on an extensive dataset and includes an advanced protein prediction function
• The launch is expected to enhance Evaxion’s ability to rapidly and effectively discover AI-derived novel vaccines and is expected to further strengthen the strong interest in AI-Immunology™ from potential partners.
• New data demonstrates EDEN™’s improved performance
  will be presented today at the
  European Conference on Computational Biology in Turku, Finland

COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specialized in the development of AI-Immunology™-powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update to its EDEN™ AI prediction model. Among other enhancements, the model can now predict toxin antigens, enabling the development of improved bacterial vaccines.

Bacterial toxins are often key contributors to disease, making their neutralization essential for the development of effective vaccines. The enhanced EDEN™ model improves the prediction of bacterial toxins for vaccine development. With greater speed and accuracy, it enables Evaxion to rapidly identify critical toxin targets that need to be included in vaccines.

“Today’s launch of the enhanced EDEN™ AI prediction model marks a significant milestone for Evaxion, further strengthening our AI-Immunology™ platform. As one of the few truly AI-first TechBio companies, our AI-Immunology™ platform is at the forefront of innovation. We continue to invest in its development and refinement to further enhance our ability to discover novel targets and develop advanced vaccines,” said Christian Kanstrup, CEO of Evaxion.

The AI-Immunology™ platform leverages advanced AI and machine learning technologies to design and develop novel vaccine candidates that address significant unmet needs. The AI ​​prediction models are applied in cancer and infectious diseases and are scalable to other therapeutic areas. The platform can deliver a single novel target in just 24 hours, compared to years with traditional methods, and is independent of delivery modality. The predictive capabilities of the AI-Immunology™ platform are robustly validated as the target prediction score has been shown to correlate with preclinical and clinical readouts.

The EDEN™ predictive model is one of five models that make up the AI-Immunology™ platform. It is used to identify B-cell antigens that are included in vaccines against infectious diseases. The new version 5.0 includes the following updates:

• Novel Bacterial Toxin Antigen Predictor: We trained novel machine learning models, improving the accuracy and reliability of toxin antigen prediction
• Extensive training dataset: We streamlined the process of curating additional training data from published sources using retrieval-augmented generation with large language models, followed by manual curation by domain experts
• Advanced protein feature prediction: We developed a novel building block for protein feature prediction using protein language models, improving the model architecture and its ability to predict various protein features

The data documenting the characteristics and performance of the new EDEN™ prediction model are being presented today during a poster session at the European Conference on Computational Biology (ECCB) in Turku, Finland.

ECCB presentation details:

Link to abstract on the ECBB website.

About AI-Immunology™
AI-Immunology™ is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases and cancers. By integrating the collective power of patented AI models PIONEER™, EDEN™, RAVEN™ and ObsERV™, the platform can model the complexity of the patient immune system. AI-Immunology™’s advanced computational modeling rapidly and uniquely identifies, predicts and designs vaccine candidates, revolutionizing the immunotherapy landscape by providing a holistic and personalized approach to combat rapidly evolving pathogens and malignant cells.

Contact details
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communications
+45 53 54 82 96
[email protected]

About EVAXION

Evaxion Biotech A/S is a breakthrough TechBio company based on its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI predictive models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases and viral infections. Based on AI-Immunology™, Evaxion has developed a clinical oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its breakthrough AI-Immunology™ platform and vaccine pipeline, visit our website.

Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target”, “believe”, “expect”, “hope”, “aim”, “imtent”, “implies”, “may”, “could”, “anticipate”, “consider”, “continue”, “estimate”, “plan”, “potential”, “predict”, “project”, “will”, “may have”, “likely”, “should”, “would”, “would”, and other words and terms of similar meaning identify forward-looking statements. Actual results could differ materially from those indicated by such forward-looking statements due to various factors, including, but not limited to, risks relating to: our financial condition and need for additional capital; our development work; costs and success of our product development activities and preclinical and clinical trials; commercialization of any approved pharmaceutical product developed using our AI platform technology, including the speed and extent of market acceptance of our product candidates; our reliance on third parties, including for the conduct of clinical trials and product manufacturing; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business of the ongoing global COVID-19 pandemic and the ongoing conflict in the Ukraine-Russia and Middle East regions; and other uncertainties affecting our business and financial condition. For a further discussion of these risks, we refer you to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.govWe assume no obligation to update any forward-looking statements, except as required by law.

Source: Evaxion Biotech